FDA approves Prism Pharmaceutical’s treatment for arrhythmia
LENEXA, Kan. The Food and Drug Administration has approved a new drug for treating arrhythmia.
CyDex Pharmaceuticals announced Monday that Prism Pharmaceuticals had won approval for Nexterone (amiodarone IV), a drug developed using CyDex’s Captisol drug-development platform. CyDex said the platform improves the water solubility and stability of active pharmaceutical ingredients.
“Prism licensed the worldwide rights to an amiodarone formulation developed with Captisol technology from CyDex in early 2006, and we have worked closely with Prism in providing technical support since then,” CyDex president and CEO Theron Odlaug said in a statement.
Researchers test administering medication using nanotechnology, gold
NEW YORK Researchers have developed a way to use tiny particles of gold to control the administration of drugs for diseases such as cancer, according to a study published in the journal ACS Nano.
The researchers, at the Massachusetts Institute of Technology, created a device that shines infrared light on particles of gold coated with medicine.
The particles vary in size, causing them to melt at different rates depending on the intensity of the light.
The researchers said the device would allow medicine to target specific areas of the body at specific rates, thus minimizing damage to healthy tissue.
N.J. tests new law requiring vaccinations for school-age children
TRENTON, N.J. New Jersey will find out this week if its new law requiring flu vaccinations for schoolchildren has worked, according to published reports.
The state is the first in the country to require schoolchildren to receive flu vaccinations, between the ages of 6 months and 5 years. It required the children to receive the vaccinations by Dec. 31. Children who have not been vaccinated will not be allowed to attend school.